- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01404806
GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects
3 de julio de 2013 actualizado por: Kristine Patterson, MD, University of North Carolina, Chapel Hill
A Phase 1, Open Label, Study in Healthy Female Subjects to Describe GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue Following Single and Multiple Dosing of GSK1349572
The purpose of this study is to describe drug concentrations of an investigational HIV medication, GSK1349572, in blood plasma, cervicovaginal fluid, vaginal and cervical tissue in HIV negative women.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Descripción detallada
Purpose: The purpose of this study is to describe first dose and steady state pharmacokinetics of GSK1349572 in cervicovaginal fluid (CVF) and vaginal (VT) and cervical (CT) tissue compared to blood plasma (BP) in HIV-1 negative women.
Based on current literature, GSK1349572 has demonstrated a desirable pharmacokinetic profile in BP, including low to moderate pharmacokinetic variability (CV% 9-41), extended t1/2 (13-15h) and trough concentrations which remain 25-fold higher than the protein-adjusted IC90 ~0.064µg/mL for wild type virus.
Understanding pharmacokinetic behavior of GSK1349572 in multiple female biological compartments will inform its role in sterilizing the genital tract in HIV-infected women, as well as protect mucosal tissue against HIV infection (pre/post-exposure prophylaxis).
Tipo de estudio
Intervencionista
Inscripción (Actual)
10
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27599
- University of North Carolina, Chapel Hill
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 35 años (Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Femenino
Descripción
Inclusion Criteria:
- Healthy pre-menopausal female subjects between the ages of 18 and 35 years, inclusive, with an intact uterus and cervix.
- Body Mass Index (BMI) of approximately 18-30 kg/m2 and a total body weight of >50kg (110 lbs)
Negative serum pregnancy test at screening and should be using at least one of the following methods of contraception:
- Abstinence
- Bilateral tubal ligation
- Condom with spermicidal gel or foam
- Stable male partner who has had a vasectomy, or stable female only partners
- Hormonal contraceptives (oral) provided the subject remains on the treatment until the follow-up visit and has been using oral contraceptives for at least 3 months prior to the first dose of trial medication
- Must agree to abstain from use of intravaginal products for 72 hours prior to the screening visit
- Must agree to abstain from any sexual activity for 72 hours prior to the Day 1 study visit and through study completion
- Previous gynecological examination with documentation of a normal Pap smear within the last year as part of clinical care
- Regular menstrual cycles with at least 21 days between menses (unless on contraception that causes amenorrhea or irregular menses)
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
- History of hysterectomy, loop electrosurgical excision procedure (LEEP), conization or cryosurgery
- Pregnant or lactating
- Unwilling to refrain from sexual intercourse or from using intra-vaginal medications/products from 72 hours prior to Day 1 until discharge from the study
- Any condition possibly affecting drug absorption (eg, gastrectomy)
- Positive urine drug screen
- Active hepatitis B infection
- Active hepatitis C infection
- A positive test for bacterial vaginosis, syphilis, gonorrhea, chlamydia, HIV, HSV-2 (active lesions) or trichomonas at screening
- History of regular use of tobacco- or nicotine-containing products exceeding 5 cigarettes per day within 3 months prior to screening
- History of regular alcohol consumption exceeding 14 drinks [1 drink = 5 ounces (150mL)] of wine or 12 ounces (360mL) of beer or 1.5 ounces (45mL) of spirits per week
- History of bleeding or clotting disorders
- Documented allergic reaction to lidocaine, silver nitrate, ferric subsulfate solution (Monsel's solution) or any iron containing products.
- Treatment with an investigational drug within 4 months preceding the first dose of trial medication.
- Use of clinically significant prescription or non-prescription drugs within 7 days prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- Blood donation of approximately 1 pint (500mL) within 56 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling to abstain from alcohol use from 48 hours prior to the first dose of study medication until after the follow-up visit.
- Using an intrauterine device for contraception.
- Using depo-medroxyprogesterone (DepoProvera®) for contraception.
- Systolic blood pressure is outside the range of 90-140mmHg, diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100 bpm for female subjects even after a single repeat reading.
- Any clinically significant abnormalities to pulse or conduction observed on screening ECG
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: GSK1349572
|
Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days.
GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h.
Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point.
Samples will be collected from 2 subjects per time point.
BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Area under the concentration time curve in blood plasma after a single dose
Periodo de tiempo: 24 hours
|
The area under the concentration time curve will be determined from all sample collection time points over a 24 hour period for blood plasma.
Sample collection will occur pre-dose, then 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours post-dose.
AUCs will be determined for individual subjects and for all subjects combined.
|
24 hours
|
Peak Concentration (Cmax) after a single dose in blood plasma
Periodo de tiempo: 24 hours
|
Peak drug concentrations in blood plasma will be determine from samples taken pre-dose, then at 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours post-dose after a first dose in each subject and across all subjects
|
24 hours
|
Area under the concentration time curve in cervicovaginal fluid after a single dose
Periodo de tiempo: 24 hours
|
The area under the concentration time curve will be determined from all sample collection time points over a 24 hour period for cervicovaginal fluid.
Sample collection will occur pre-dose, then 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours post-dose.
AUCs will be determined for individual subjects and for all subjects combined.
|
24 hours
|
Area under the concentration time curve in cervical and vaginal tissue after a single dose
Periodo de tiempo: 24 hours
|
The area under the concentration time curve will be determined from all sample collection time points over a 24 hour period for cervical and vaginal tissue samples.
Sample collection will occur at one time point per subject, either at 3, 6, 12, or 24 hours post-dose.
AUCs will be determined for all subjects combined.
|
24 hours
|
Peak Concentration (Cmax) after a single dose in cervicovaginal fluid
Periodo de tiempo: 24 hours
|
Peak drug concentrations in cervicovaginal fluid will be determine from samples taken pre-dose, then at 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours post-dose after a first dose in each subject and across all subjects
|
24 hours
|
Peak Concentration (Cmax) after a single dose in cervical and vaginal tissue
Periodo de tiempo: 24 hours
|
Peak drug concentrations in cervical and vaginal tissue will be determine from samples taken at one time point per subject at either 3, 6, 12, or 24 hours post-dose after a first dose across all subjects
|
24 hours
|
Area under the concentration time curve for cervicovaginal fluid at steady state
Periodo de tiempo: 72 hours
|
The area under the concentration time curve will be determined from all sample collection time points over a 72 hour period for cervicovaginal fluid after steady state is reached.
Sample collection will occur pre-dose, then at 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 48, and 72 hours post-dose.
|
72 hours
|
Area under the concentration time curve in cervical and vaginal tissue at steady state
Periodo de tiempo: 24 hours
|
The area under the concentration time curve will be determined from all sample collection time points over a 24 hour period for cervical/vaginal tissue after steady state is reached.
Sample collection will occur at one time point per subject, either 3, 6, 12 or 24 hours post dose and the combined data from all subjects will be used to determine the AUC.
|
24 hours
|
Peak concentration (Cmax) in cervicovaginal fluid at steady state
Periodo de tiempo: 72 hours
|
Peak drug concentrations in cervicovaginal fluid will be determined at steady state in each subject and across all subjects.
Samples will be collected pre-dose, then at 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 48, and 72 hours post-dose.
|
72 hours
|
Peak concentration (Cmax) in blood plasma at steady state
Periodo de tiempo: 24 hours
|
Peak drug concentrations in cervical/vaginal tissue will be determined at steady state.
Each subject will have samples collected at one time point, either 3, 6, 12, or 24 hours post-dose and the peak will be determined by the combined data of all subjects
|
24 hours
|
Area under the concentration time curve in blood plasma at steady state
Periodo de tiempo: 72 hours
|
The area under the concentration time curve will be determined from all sample collection time points over a 72 hour period for blood plasma.
Sample collection will occur pre-dose, then 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 48, and 72 hours post-dose.
AUCs will be determined for individual subjects and for all subjects combined.
|
72 hours
|
Peak concentration (Cmax) in blood plasma at steady state
Periodo de tiempo: 72 hours
|
Peak drug concentrations in blood plasma will be determined at steady state in each subject and across all subjects.
Samples will be collected pre-dose, then at 1, 2, 3, 4, 5, 6, 8, 12, 18, 24, 48, and 72 hours post-dose.
|
72 hours
|
Area under the concentration time curve ratios after a single dose
Periodo de tiempo: 24 hours
|
AUC ratios will be determined to compare blood plasma concentrations after a single dose with concentrations in cervicovaginal and cervical and vaginal tissues.
|
24 hours
|
Area under the concentration time curve ratios at steady state
Periodo de tiempo: 72 hours
|
AUC ratios will be determined to compare concentrations in cervicovaginal fluid and tissues to blood plasma concentrations at steady state.
|
72 hours
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kristine B. Patterson, M.D., University of North Carolina, Chapel Hill
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de agosto de 2011
Finalización primaria (Actual)
1 de agosto de 2012
Finalización del estudio (Actual)
1 de septiembre de 2012
Fechas de registro del estudio
Enviado por primera vez
25 de julio de 2011
Primero enviado que cumplió con los criterios de control de calidad
26 de julio de 2011
Publicado por primera vez (Estimar)
28 de julio de 2011
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
4 de julio de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
3 de julio de 2013
Última verificación
1 de julio de 2013
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 11-1011
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre GSK1349572 (dolutegravir)
-
ViiV HealthcareGlaxoSmithKline; ShionogiTerminadoInfecciones por VIHEstados Unidos
-
ViiV HealthcareGlaxoSmithKline; ShionogiTerminadoInfección por el Virus de la Inmunodeficiencia Humana IAlemania, España, Francia, Australia, Estados Unidos, Canadá, Reino Unido, Italia, Federación Rusa
-
ViiV HealthcareGlaxoSmithKlineTerminadoInfección, Virus De La Inmunodeficiencia HumanaEstados Unidos
-
GlaxoSmithKlineShionogiTerminadoVoluntario SaludableEstados Unidos
-
University of North Carolina, Chapel HillGlaxoSmithKlineTerminadoGSK1349572 Exposición en sangre, fluido seminal y fluido y tejido rectal en sujetos masculinos sanosSaludableEstados Unidos
-
ViiV HealthcareGlaxoSmithKline; ShionogiTerminadoInfecciones por VIH | Infección, Virus De La Inmunodeficiencia HumanaEstados Unidos, Francia, Países Bajos, España, Taiwán, Australia, Bélgica, Federación Rusa, Canadá, Reino Unido, México, Italia, Sudáfrica, Rumania, Argentina, Hungría, Polonia, Chile, Grecia, Brasil
-
ViiV HealthcareGlaxoSmithKline; ShionogiTerminadoInfección, Virus De La Inmunodeficiencia HumanaEstados Unidos
-
ViiV HealthcareGlaxoSmithKline; ShionogiTerminadoInfecciones por VIH | Infección, Virus De La Inmunodeficiencia HumanaEstados Unidos
-
ViiV HealthcareGlaxoSmithKline; ShionogiTerminadoInfecciones por VIH | Sujetos sanos | Deterioro hepático | Infección, Virus De La Inmunodeficiencia HumanaEstados Unidos
-
GlaxoSmithKlineShionogiTerminado